Clinical trials: Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes Mellitus
TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
Basal nitric oxide (NO) activity plays a pivotal role in the regulation of glomerular hemodynamics, and in animal experiments its alteration has been associated with morphological changes characteristic of diabetic nephropathy.
- Trial name
- NCT00905528
- Testing
- Telmisartan 80 mg/d, Ramipril 10 mg/d
- Where
- Germany
- Volunteers
- 69 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 Diabetes Mellitus treated with insulin.
- Trial name
- PIONEER 8 (NCT03021187)
- Testing
- semaglutide
- Where
- 118 sites in United States, Canada and 8 more
- Volunteers
- 731 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of TG103 in Subjects With Type 2 Diabetes
The main purpose of this study is to assess the safety and tolerability of multiple ascending doses of TG103 in subjects with type 2 diabetes.
- Trial name
- NCT04790006
- Testing
- TG103
- Volunteers
- 54 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diabetes Mellitus, Type 2
A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes
The study compares 2 medicines for type 2 diabetes: oral semaglutide (a new medicine) and placebo (a dummy medicine). Researchers will test semaglutide to see how well it works compared to placebo.
- Trial name
- PIONEER 11 (NCT04109547)
- Testing
- Oral semaglutide
- Where
- 66 sites in Algeria, China and 4 more
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
Albiglutide, a novel analogue of glucagon-like peptide-1 (GLP-1), has been developed and approved for the treatment of type 2 diabetes mellitus.
- Trial name
- NCT02496221
- Testing
- Albiglutide 50 mg, CCK (Kinevac)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.
This is an escalating dose study in subjects with T2DM, which will consist of four overlapping cohorts receiving 6 days of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics.
- Trial name
- NCT00733577
- Testing
- SB756050
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetic Nephropathy
A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy
PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845…
- Trial name
- NCT01488877
- Testing
- PF-03882845, Spironolactone
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HGR4113 in Healthy Subjects
1. Study Objective: The objective of this study is to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics, and food effect of HGR4113 after single and multiple oral administration in healthy…
- Trial name
- NCT05642377
- Testing
- HGR4113
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaceum
Type 2 Diabetes Mellitus
Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects
To assess the effect of PEX168 doses on the pharmacokinetics of simvastatin(as determined by simvastation acid) in healthy subjects. To assess the safety of single doses of simvastation administered with and without PEX168
- Trial name
- NCT02447601
- Testing
- PEX168, Simvastatin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes or Obesity Without Diabetes
Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.
Animal studies have shown that stimulation of the lingual lipid-receptor, CD 36, is accompanied by the rapid secretion of hormones in the digestive tract (incretines).
- Trial name
- NCT02028975
- Testing
- Measure the threshold of detection for linoleic acid, Oral stimulation tests, Venous blood samples
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control and complications in diabetic subjects in Asia.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00836030)
- Testing
- No treatment given
- Where
- Singapore
- Volunteers
- 854 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel dose cohort, multiple dose study to evaluate the efficacy, safety, and tolerability of different doses of PB-119 in drug-naïve subjects with T2DM.
- Trial name
- NCT03520972
- Testing
- PB-119 75ug, PB-119 150ug, PB-119 200ug
- Where
- China
- Volunteers
- 251 people
- Sponsor
- PegBio Co., Ltd.
Metabolic Syndrome, Obesity
Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism
Professor Matti Uusitupa, University of Kuopio, Department of Clinical Nutrition (www.uku.fi) Docent Matej Oresic, VTT (www.vtt.fi) Ursula Schwab, PhD, Docent, Marjukka Kolehmainen, PhD, Docent, Leena Pulkkinen, PhD, Docent…
- Conditions
- Metabolic Syndrome, Obesity, Impaired Glucose Tolerance, Impaired Fasting Glucose
- Trial name
- Sysdimet (NCT00573781)
- Testing
- Diet with increased intake of rye bread, berries and fish, Increased intake of whole grain and rye bread, Control diet with decreased intake of rye bread, berries and fish
- Where
- Finland
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Marjukka Kolehmainen
T2DM (Type 2 Diabetes Mellitus)
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
This double-masked placebo-controlled study will include approximately 450 subjects with inadequately controlled T2DM on diet control alone or on diet control and metformin monotherapy.
- Trial name
- NCT04754334
- Testing
- ORMD-0801
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Oramed, Ltd.
Diabetes Mellitus
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes
This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®.
- Trial name
- NCT00136916
- Testing
- Inhaled Insulin, Subcutaneous insulin
- Where
- 92 sites in United States, Brazil and 2 more
- Volunteers
- 635 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
This trial is a multi-center, randomized, double-blind, placebo-controlled parallel group, Phase 2 study in subjects with Type 2 diabetes mellitus on a stable dose of metformin to evaluate the safety and efficacy of TTP273 versus…
- Trial name
- NCT02653599
- Testing
- TTP273
- Where
- 30 sites in United States
- Volunteers
- 174 people
- Sponsor
- vTv Therapeutics
Glucose Intolerance, Impaired Insulin Secretion
The Effect of Anakinra on Insulin Secretion
Rationale: Once diabetes develops, β-cell function progressively deteriorates and therapeutic approaches that prevent of delay loss of β-cell function are needed in the treatment of type 2 diabetes mellitus.
- Conditions
- Glucose Intolerance, Impaired Insulin Secretion, Diabetes Mellitus Type 2
- Trial name
- NCT01285232
- Testing
- Anakinra
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
This is a phase 1 multiple ascending dose (MAD) study, conducted in subjects with Type 2 Diabetes Mellitus.
- Trial name
- NCT03332836
- Testing
- HM12460A
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Type 2
A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)
A study to test the pharmacokinetics after twice daily administration of MK-0941 or placebo in subjects with type 2 diabetes who have inadequate control on metformin.
- Trial name
- NCT00873821
- Testing
- MK-0941
- Volunteers
- 44 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic…
- Trial name
- ARTS-HF (NCT01807221)
- Testing
- Finerenone (BAY94-8862), Inspra (eplerenone)
- Where
- 172 sites in United States, Australia and 23 more
- Volunteers
- 1,066 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.